 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes THIOTHIXENE increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"thiothixene"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: THIOTHIXENE: precautions: PRECAUTIONS An antiemetic effect was observed in animal studies with thiothixene; since this effect may also occur in man, it is possible that thiothixene may mask [0m
[31msigns of overdosage of toxic drugs and may obscure conditions such as intestinal obstruction and brain tumor. In consideration of the known capability of thiothixene and certain other psychotropic [0m
[31mdrugs to precipitate convulsions, extreme caution should be used in patients with a history of convulsive disorders or those in a state of alcohol withdrawal, since it may lower the convulsive [0m
[31mthreshold. Although thiothixene potentiates the actions of the barbiturates, the dosage of the anticonvulsant therapy should not be reduced when thiothixene is administered concurrently. Though [0m
[31mexhibiting rather weak anticholinergic properties, thiothixene should be used with caution in patients who might be exposed to extreme heat or who are receiving atropine or related drugs. THIOTHIXENE:[0m
[31mprecautions: Use with caution in patients with cardiovascular disease. Caution as well as careful adjustment of the dosages is indicated when thiothixene is used in conjunction with other CNS [0m
[31mdepressants. Also, careful observation should be made for pigmentary retinopathy and lenticular pigmentation [0m[1;31m([0m[31mfine lenticular pigmentation has been noted in a small number of patients treated with [0m
[31mthiothixene for prolonged periods[0m[1;31m)[0m[31m. Blood dyscrasias [0m[1;31m([0m[31magranulocytosis, pancytopenia, thrombocytopenic purpura[0m[1;31m)[0m[31m, and liver damage [0m[1;31m([0m[31mjaundice, biliary stasis[0m[1;31m)[0m[31m have been reported with related drugs. [0m
[31mAntipsychotic drugs, including thiothixene [0m[1;31m3[0m[31m , elevate prolactin levels; the elevation persists during chronic administration. THIOTHIXENE: precautions: Tissue culture experiments indicate that [0m
[31mapproximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously [0m
[31mdetected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown [0m
[31mfor most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date,[0m
[31mhowever, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. THIOTHIXENE:[0m
[31mprecautions: Leukopenia, Neutropenia and Agranulocytosis Class Effect In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia and agranulocytosis have been reported [0m
[31mtemporally related to antipsychotic agents. Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count [0m[1;31m([0m[31mWBC[0m[1;31m)[0m[31m and history of drug induced leukopenia/neutropenia. [0m
[31mPatients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count [0m[1;31m([0m[31mCBC[0m[1;31m)[0m[31m monitored frequently during the first few months of [0m
[31mtherapy and discontinuation of thiothixene should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients with clinically [0m
[31msignificant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. THIOTHIXENE: precautions: Patients with [0m
[31msevere neutropenia [0m[1;31m([0m[31mabsolute neutrophil count < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m should discontinue thiothixene and have their WBC followed until recovery. Information for Patients Given the likelihood that some patients [0m
[31mexposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The [0m
[31mdecision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided. Drug [0m
[31mInteractions Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. Patients receiving these drugs should be observed for [0m
[31msigns of reduced thiothixene effectiveness [0m[1;31m4[0m[31m,[0m[1;31m5[0m[31m . THIOTHIXENE: precautions: Due to a possible additive effect with hypotensive agents, patients receiving these drugs should be observed closely for [0m
[31msigns of excessive hypotension when thiothixene is added to their drug regimen [0m[1;31m6[0m[31m .         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: warnings: WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are [0m
[31mat an increased risk of death. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee BOXED WARNING [0m[1;31m)[0m[31m. Tardive Dyskinesia Tardive dyskinesia, a syndrome [0m
[31mconsisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs, including thiothixene [0m[1;31m1[0m[31m . Although the prevalence of the syndrome [0m
[31mappears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely[0m
[31mto develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. THIOTHIXENE: warnings: Both the risk of developing the syndrome and the [0m
[31mlikelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, [0m
[31mthe syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the [0m
[31msyndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress [0m[1;31m([0m[31mor partially suppress[0m[1;31m)[0m[31m the signs and symptoms of the [0m
[31msyndrome and thereby may possibly mask the underlying disease process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, [0m
[31mantipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. THIOTHIXENE: warnings: Chronic antipsychotic treatment should generally be [0m
[31mreserved for patients who suffer from a chronic illness that, [0m[1;31m1[0m[1;31m)[0m[31m is known to respond to antipsychotic drugs, and [0m[1;31m2[0m[1;31m)[0m[31m for whom alternative, equally effective, but potentially less harmful treatments are[0m
[31mnot available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The [0m
[31mneed for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, [0m
[31msome patients may require treatment despite the presence of the syndrome. [0m[1;31m([0m[31mFor further information about the description of tardive dyskinesia and its clinical detection, please refer to â€œ Information[0m
[31mfor Patients â€ in the PRECAUTIONS section, and to the ADVERSE REACTIONS section.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs [0m
[31mare at an increased risk of death. Analyses of seventeen placebo-controlled trials [0m[1;31m([0m[31mmodal duration of [0m[1;31m10[0m[31m weeks[0m[1;31m)[0m[31m, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in [0m
[31mdrug-treated patients of between [0m[1;31m1.6[0m[31m to [0m[1;31m1.7[0m[31m times the risk of death in placebo-treated patients. Over the course of a typical [0m[1;31m10[0m[31m-week controlled trial, the rate of death in drug-treated patients was [0m
[31mabout [0m[1;31m4.5[0m[31m%, compared to a rate of about [0m[1;31m2.6[0m[31m% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular [0m[1;31m([0m[31me.g., heart failure, sudden death[0m[1;31m)[0m
[31mor infectious [0m[1;31m([0m[31me.g., pneumonia[0m[1;31m)[0m[31m in nature. THIOTHIXENE: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may [0m
[31mincrease mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some [0m[1;31mcharacteristic[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m of the patients is[0m
[31mnot clear. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:THIOTHIXENE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"thiothixene"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does THIOTHIXENE increase or decrease the risk of [0m
[31mhip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hip fracture?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes THIOTHIXENE increase or decrease the risk of hip fracture?[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of hip fracture?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"thiothixene"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: THIOTHIXENE: precautions: PRECAUTIONS An antiemetic effect was observed in animal studies with thiothixene; since this effect may also occur in man, it is possible that thiothixene may mask [0m
[31msigns of overdosage of toxic drugs and may obscure conditions such as intestinal obstruction and brain tumor. In consideration of the known capability of thiothixene and certain other psychotropic [0m
[31mdrugs to precipitate convulsions, extreme caution should be used in patients with a history of convulsive disorders or those in a state of alcohol withdrawal, since it may lower the convulsive [0m
[31mthreshold. Although thiothixene potentiates the actions of the barbiturates, the dosage of the anticonvulsant therapy should not be reduced when thiothixene is administered concurrently. Though [0m
[31mexhibiting rather weak anticholinergic properties, thiothixene should be used with caution in patients who might be exposed to extreme heat or who are receiving atropine or related drugs. THIOTHIXENE:[0m
[31mprecautions: Use with caution in patients with cardiovascular disease. Caution as well as careful adjustment of the dosages is indicated when thiothixene is used in conjunction with other CNS [0m
[31mdepressants. Also, careful observation should be made for pigmentary retinopathy and lenticular pigmentation [0m[1;31m([0m[31mfine lenticular pigmentation has been noted in a small number of patients treated with [0m
[31mthiothixene for prolonged periods[0m[1;31m)[0m[31m. Blood dyscrasias [0m[1;31m([0m[31magranulocytosis, pancytopenia, thrombocytopenic purpura[0m[1;31m)[0m[31m, and liver damage [0m[1;31m([0m[31mjaundice, biliary stasis[0m[1;31m)[0m[31m have been reported with related drugs. [0m
[31mAntipsychotic drugs, including thiothixene [0m[1;31m3[0m[31m , elevate prolactin levels; the elevation persists during chronic administration. THIOTHIXENE: precautions: Tissue culture experiments indicate that [0m
[31mapproximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously [0m
[31mdetected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown [0m
[31mfor most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date,[0m
[31mhowever, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. THIOTHIXENE:[0m
[31mprecautions: Leukopenia, Neutropenia and Agranulocytosis Class Effect In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia and agranulocytosis have been reported [0m
[31mtemporally related to antipsychotic agents. Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count [0m[1;31m([0m[31mWBC[0m[1;31m)[0m[31m and history of drug induced leukopenia/neutropenia. [0m
[31mPatients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count [0m[1;31m([0m[31mCBC[0m[1;31m)[0m[31m monitored frequently during the first few months of [0m
[31mtherapy and discontinuation of thiothixene should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Patients with clinically [0m
[31msignificant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. THIOTHIXENE: precautions: Patients with [0m
[31msevere neutropenia [0m[1;31m([0m[31mabsolute neutrophil count < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m should discontinue thiothixene and have their WBC followed until recovery. Information for Patients Given the likelihood that some patients [0m
[31mexposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The [0m
[31mdecision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided. Drug [0m
[31mInteractions Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. Patients receiving these drugs should be observed for [0m
[31msigns of reduced thiothixene effectiveness [0m[1;31m4[0m[31m,[0m[1;31m5[0m[31m . THIOTHIXENE: precautions: Due to a possible additive effect with hypotensive agents, patients receiving these drugs should be observed closely for [0m
[31msigns of excessive hypotension when thiothixene is added to their drug regimen [0m[1;31m6[0m[31m .         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: warnings: WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are [0m
[31mat an increased risk of death. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee BOXED WARNING [0m[1;31m)[0m[31m. Tardive Dyskinesia Tardive dyskinesia, a syndrome [0m
[31mconsisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs, including thiothixene [0m[1;31m1[0m[31m . Although the prevalence of the syndrome [0m
[31mappears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely[0m
[31mto develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. THIOTHIXENE: warnings: Both the risk of developing the syndrome and the [0m
[31mlikelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, [0m
[31mthe syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the [0m
[31msyndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress [0m[1;31m([0m[31mor partially suppress[0m[1;31m)[0m[31m the signs and symptoms of the [0m
[31msyndrome and thereby may possibly mask the underlying disease process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, [0m
[31mantipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. THIOTHIXENE: warnings: Chronic antipsychotic treatment should generally be [0m
[31mreserved for patients who suffer from a chronic illness that, [0m[1;31m1[0m[1;31m)[0m[31m is known to respond to antipsychotic drugs, and [0m[1;31m2[0m[1;31m)[0m[31m for whom alternative, equally effective, but potentially less harmful treatments are[0m
[31mnot available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The [0m
[31mneed for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, [0m
[31msome patients may require treatment despite the presence of the syndrome. [0m[1;31m([0m[31mFor further information about the description of tardive dyskinesia and its clinical detection, please refer to â€œ Information[0m
[31mfor Patients â€ in the PRECAUTIONS section, and to the ADVERSE REACTIONS section.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs [0m
[31mare at an increased risk of death. Analyses of seventeen placebo-controlled trials [0m[1;31m([0m[31mmodal duration of [0m[1;31m10[0m[31m weeks[0m[1;31m)[0m[31m, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in [0m
[31mdrug-treated patients of between [0m[1;31m1.6[0m[31m to [0m[1;31m1.7[0m[31m times the risk of death in placebo-treated patients. Over the course of a typical [0m[1;31m10[0m[31m-week controlled trial, the rate of death in drug-treated patients was [0m
[31mabout [0m[1;31m4.5[0m[31m%, compared to a rate of about [0m[1;31m2.6[0m[31m% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular [0m[1;31m([0m[31me.g., heart failure, sudden death[0m[1;31m)[0m
[31mor infectious [0m[1;31m([0m[31me.g., pneumonia[0m[1;31m)[0m[31m in nature. THIOTHIXENE: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may [0m
[31mincrease mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some [0m[1;31mcharacteristic[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m of the patients is[0m
[31mnot clear. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:THIOTHIXENE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDAHandler has responded with DO-NOT-KNOW, which indicates that the [0m
[32mFDA label for thiothixene does not contain information regarding its effects on the risk of hip fracture. This means that there is no verified information available from the FDA label that specifies [0m
[32mwhether thiothixene increases or decreases the risk of hip fracture. Therefore, I cannot provide a definitive answer to the question based on FDA label data. [0m

[32mThe absence of information in the FDA label could mean that there has not been a confirmed link established between thiothixene and hip fractures, or that it has not been studied or reported in a [0m
[32mmanner that would lead to inclusion in the label. It is important to note that this does not necessarily imply that thiothixene has no effect on the risk of hip fractures; rather, it means that there [0m
[32mis no information available in the FDA label to answer this question. [0m

[32mFor a more comprehensive understanding of the potential risks associated with thiothixene, including its impact on the risk of hip fractures, consultation with medical literature or clinical studies [0m
[32mmay be necessary. However, based on the FDA label data alone, the answer must be DO-NOT-KNOW.[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hip fracture?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether thiothixene increases or decreases the risk of hip fracture."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for thiothixene does not contain information regarding its effects on the risk of hip fracture."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does THIOTHIXENE increase or decrease the risk of hip fracture?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether thiothixene increases or decreases the risk of hip fracture."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for thiothixene does not contain information regarding its effects on the risk of hip fracture."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does THIOTHIXENE increase or decrease the risk of hip fracture?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether thiothixene increases or decreases the risk of hip fracture.[0m
[1;31m2[0m[31m. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for thiothixene does not contain information regarding its effects on the risk of hip fracture.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hip fracture-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for thiothixene does not contain information regarding its effects on the risk of hip fracture, as indicated by the response of DO-NOT-KNOW from FDAHandler. Therefore, it is not possible[0m
[32mto determine from the FDA label data whether thiothixene increases or decreases the risk of hip fracture.[0m
